Alterity To Initiate Phase 3 Trial Of ATH434 In MSA Subsequent To Receipt Of EOP2 Minutes From FDA

Alterity Therapeutics (ATHE) received the FDA’s meeting minutes for the End-of Phase 2 (EOP2) review of ATH434 in Multiple System Atrophy (MSA). The update is informational rather than a decision or new clinical outcome, so near-term impact is likely limited. Overall read-through appears neutral pending any guidance contained in the minutes.

Analysis

Alterity Therapeutics (ATHE) received the FDA’s meeting minutes for the End-of Phase 2 (EOP2) review of ATH434 in Multiple System Atrophy (MSA). The update is informational rather than a decision or new clinical outcome, so near-term impact is likely limited. Overall read-through appears neutral pending any guidance contained in the minutes.